Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Macropinocytic dextran facilitates KRAS-targeted delivery while reducing drug-induced tumor immunity depletion in pancreatic cancer.

Theranostics - 1 Jan 2022

Yuan Fang, Sun Mengnan, Liu Zhengsheng, Liu Huiqin, Kong Weijian, Wang Rui, Qian Feng

Abstract excerpt

Background: Pancreatic cancer comprises not only cancer cells but also a collection of cross-talking noncancerous cells within tumor. Therefore, selective delivery of cytotoxic agents towards cancer cells and limiting the collateral damage to tumor suppressive benign cells, such as effector lymphocytes in the tumor microenvironment, is of great value. Methods: Pancreatic cancer cells harbor oncogenic KRAS which...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Dextrans
Share to Diterpenes
Share to Epoxy Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Targeted Therapy

Share to Pancreatic Neoplasms

Share to Phenanthrenes

Share to Proto-Oncogene Proteins p21(ras)

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 35154474
DOI: 10.7150/thno.65299
PMCID: PMC8771557

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Macropinocytic dextran facilitates KRAS-targeted delivery while reducing drug-induced tumor immunity depletion in pancreatic cancer.PMID 35154474Read ↗

Exploiting macropinocytosis for drug delivery into KRAS mutant cancer.Semantic proximity Read ↗

A recombinantly tailored β-defensin that displays intensive macropinocytosis-mediated uptake exerting potent efficacy against K-Ras mutant pancreatic cancer.Semantic proximity Read ↗

Novel selective inhibitors of macropinocytosis-dependent growth in pancreatic ductal carcinoma.Semantic proximity Read ↗

Intracellular nanoparticle delivery by oncogenic KRAS-mediated macropinocytosisSemantic proximity Read ↗

KRAS mutation-driven enhanced macropinocytosis: using albumin as a trojan horse for delivering nanomedicine.Semantic proximity Read ↗

Stimulating macropinocytosis of peptide-drug conjugates through DNA-dependent protein kinase inhibition for treating KRAS-mutant cancer.Semantic proximity Read ↗

An in situ immunogenicity-amplifying payload delivery system for immunotherapy of Kirsten rat sarcoma viral oncogene homolog-mutant cancer.Semantic proximity Read ↗

Targeted nanodelivery of siRNA against KRAS G12D inhibits pancreatic cancer.Semantic proximity Read ↗

Ferritin-based nanocarrier delivery of KRAS G12D inhibitor in pancreatic adenocarcinoma cells and patient-derived organoids: A novel approach for treatment.Semantic proximity Read ↗

Synthetically Lethal Biomimetic Nutri-hijacker Hitchhikes and Reprograms KRAS Mutation-Driven Metabolic Addictions for Pancreatic Ductal Adenocarcinoma Treatment.Semantic proximity Read ↗

Albumin-conjugated drug is irresistible by single gene mutation of endocytic system: Verification by genome-wide CRISPR-Cas9 loss-of-function screens.Semantic proximity Read ↗

Nano-delivery of Gemcitabine Derivative as a Therapeutic Strategy in a Desmoplastic KRAS Mutant Pancreatic Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.